This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexza Pharma: Premium Selling Options Strategy

NEW YORK ( TheStreet) -- Alexza Pharmaceuticals (ALXA - Get Report) has a FDA drug approval decision date for its Adasuve treatment of agitation associated with schizophrenia and bipolar disorder on Dec. 21, 2012. Options currently imply of move of around $3 per share (up to $8 per share or down to $2 per share.)

Adasuve has faced a challenging path to approval and so the upcoming FDA decision, either positive or negative, remains uncertain. In situations where uncertainty is high and premiums are expensive, it is often a good idea to sell premium in a directionally neutral manner.

Here is the trade:

Sell (10) JAN 4.0 strike Puts at 0.95 = $(950)
Sell (10) JAN 7.0 strike Calls at 0.95 = $(950)

Initial P&L = $(1,900) Credit

This is a short Strangle sold for a credit of $1,900. Maximum profit occurs between $4 and $7 and is equal to the premium sold, or $1,900. The trade breaks even at approximately $2 and $9 - an extremely wide range. [See P&L Diagram below.]

The key risk in the trade is that the sold Puts and Calls are naked (i.e. they are not covered.) Risk can be quite substantial if the stock moves beyond what is implied by the options market, especially on the Call side of the trade.

Pelz has no position in Alexza.

To learn more about using options to trade biotech catalysts, check out Tony Pelz's book, The Biotech Trader Handbook.
Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of Pelz currently resides in Denver, Colorado where he trades for his own account.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALXA $0.64 6.70%
AAPL $95.03 -2.90%
FB $117.50 7.90%
GOOG $691.20 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs